X4 Pharmaceuticals posts Q1 net loss as license revenue drops

X4 Pharmaceuticals

06/05/2026 12:24

Overview

Rare hematology drug developer's Q1 revenue fell sharply, missing analyst expectations

Company posted Q1 net loss after prior-year profit, as license revenue dropped

European Commission approved XOLREMDI for WHIM syndrome; Phase 3 trial enrollment on track

Outlook

X4 Pharmaceuticals expects to complete 4WARD Phase 3 trial enrollment by end of Q3 2026

Company says cash position provides runway through 2028

European commercialization of XOLREMDI to proceed via partner Norgine following EU approval

Result Drivers

LICENSE REVENUE DROP - Q1 revenue decline driven by absence of prior-year Norgine license revenue

LOWER OPERATING EXPENSES - R&D and G&A expenses decreased due to reduced headcount after 2025 restructuring

Company press release: ID:nGNXV0YDC

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Miss
$2.70 mln
$3.20 mln (3 Analysts)
Q1 EPS
-$0.16
Q1 Net Income
-$20.24 mln
Q1 Income from Operations
-$20.31 mln
Q1 Operating Expenses
$23.01 mln


Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

Wall Street's median 12-month price target for X4 Pharmaceuticals Inc is $12.00, about 185.7% above its May 5 closing price of $4.20

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)